Difference between revisions of "Team:Bielefeld-CeBiTec/Practices/DualUse"
m |
m |
||
Line 36: | Line 36: | ||
<p> We decided to do an analysis of <b>biosecurity</b>, specifically the <b>dual use issue</b> of our project. While we were scanning the literature for information about our biosensor for detection of date rape drugs, we encountered many sensitive information about the accessibility and (chemical) synthesis of date rape drugs. Those information are publicly availably. Especially the publication of a freely available ingredient raised our concern. In our opinion, this knowledge can create a threat to the health of people, if it is misused.</p> | <p> We decided to do an analysis of <b>biosecurity</b>, specifically the <b>dual use issue</b> of our project. While we were scanning the literature for information about our biosensor for detection of date rape drugs, we encountered many sensitive information about the accessibility and (chemical) synthesis of date rape drugs. Those information are publicly availably. Especially the publication of a freely available ingredient raised our concern. In our opinion, this knowledge can create a threat to the health of people, if it is misused.</p> | ||
<p>Because iGEM is an open source competition, we might ourselves provide knowledge that could be of dual use. Since iGEM asks us to be striving to be conscientious members of the synthetic biology community, we informed ourselves about existing biosafety, biosecurity and dual use regulations.</p> | <p>Because iGEM is an open source competition, we might ourselves provide knowledge that could be of dual use. Since iGEM asks us to be striving to be conscientious members of the synthetic biology community, we informed ourselves about existing biosafety, biosecurity and dual use regulations.</p> | ||
− | <p>We found the legal situation in Germany, the European Union and the USA to be inconsistent. In addition to these <b>laws</b>, many proposals from various advisory boards and <b>non governmental organizations</b> exist. We provide an overview about the proposals of these organizations and summarize various aspects of the ongoing <b>ethical discussion</b> about the opposing needs freedom of science and regulation of research with possible biosecurity issues. Therefore we contacted several experts from ethics committees, members of the German ethics council, a constitutional lawyer and a law student from the USA, as well as the iGEM safety committee itself. In fruitful discussions we obtained various opinions from different fields of expertise/from different | + | <p>We found the legal situation in Germany, the European Union and the USA to be inconsistent. In addition to these <b>laws</b>, many proposals from various advisory boards and <b>non governmental organizations</b> exist. We provide an overview about the proposals of these organizations and summarize various aspects of the ongoing <b>ethical discussion</b> about the opposing needs freedom of science and regulation of research with possible biosecurity issues. Therefore we contacted several experts from ethics committees, members of the German ethics council, a constitutional lawyer and a law student from the USA, as well as the iGEM safety committee itself. In fruitful discussions we obtained various opinions from different fields of expertise/from different academical point of views/from different perspectives.</p> |
<p>In the year 2011, the iGEM main page had a security section, that stated</p> | <p>In the year 2011, the iGEM main page had a security section, that stated</p> | ||
Line 55: | Line 55: | ||
<p><b>We believe, that iGEM can be a role model in raising awareness of biosecurity and dual use risks - for a better international collaboration to create beneficial knowledge.</b></p> | <p><b>We believe, that iGEM can be a role model in raising awareness of biosecurity and dual use risks - for a better international collaboration to create beneficial knowledge.</b></p> | ||
− | <p>We briefly summarize our findings on these pages. The detailed report is available as <b>PDF</b>.</p> | + | <p>We briefly summarize our findings on these pages. The detailed report is available as a <b>PDF</b>.</p> |
</div> | </div> | ||
Line 118: | Line 118: | ||
<p>Every team is dealing with genetically modified organisms, methods of synthetic biology to analyze, combine and build those organisms and DNA parts, respectively. Therefore, the question of regulation is given in context of biosecurity and biosafety. It needs to be dealt with within each team and the competition itself as well.</p> | <p>Every team is dealing with genetically modified organisms, methods of synthetic biology to analyze, combine and build those organisms and DNA parts, respectively. Therefore, the question of regulation is given in context of biosecurity and biosafety. It needs to be dealt with within each team and the competition itself as well.</p> | ||
<h3>Biosafety and Biosecurity in iGEM</h3> | <h3>Biosafety and Biosecurity in iGEM</h3> | ||
− | <p>However, we could not find definitions of biosafety, biosecurity, dual use and dual use research of concern (DURC) within the iGEM safety page. In terms of biosafety, obligational forms need to be filled and check-ins for certain organisms and proteins are required. A list of organizations publishing instructions and legal regulations for different countries is provided, since iGEM faces the challenge of teams from a broad range of countries. Regarding biosecurity on the other hand, we found questions to be asked in context of safe project design, such as “To whom will it be benefitial or harmful?” on the safety page. It is noticeable, that the questions asked try to cover a mixture of biosafety and biosecurity issues. The answers differ among the iGEM teams in a very broad spectrum. Interestingly, the questions aim to the designed product or the used methods/chassi | + | <p>However, we could not find definitions of biosafety, biosecurity, dual use and dual use research of concern (DURC) within the iGEM safety page. In terms of biosafety, obligational forms need to be filled and check-ins for certain organisms and proteins are required. A list of organizations publishing instructions and legal regulations for different countries is provided, since iGEM faces the challenge of teams from a broad range of countries. Regarding biosecurity on the other hand, we found questions to be asked in context of safe project design, such as “To whom will it be benefitial or harmful?” on the safety page. It is noticeable, that the questions asked try to cover a mixture of biosafety and biosecurity issues. The answers differ among the iGEM teams in a very broad spectrum. Interestingly, the questions aim to the designed product or the used methods/chassi. The information that are distributed among our society by the team´s homepages, wiki and other published materials is not addressed. In our view, the question concerning security in the safety form aim for the product rather than the knowledge too: “What risks might your project pose, if it were fully developed into a real product that real people could use? What future work might you do to reduce those risks?” We think that biosecurity risks need to be defined and the question to be asked more precisely.</p> |
<h3>Dual Use Dilemma in iGEM</h3> | <h3>Dual Use Dilemma in iGEM</h3> | ||
− | <p>Nevertheless, iGEM members are supposed to live up to the trust that is put into them by society and “design, build and share biological devices safely” (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#iGEM15">iGEM Safety Page</a>). Aspects of dual use have found focus in Terry Johnson´s call for awareness: iGEM participants, but also participants anywhere in the biotechnological environment, “should be aware of: the organization or organizations overseeing (ones) work, the appropriate Risk Group for the organisms that (one is) working with, and any select agents that might be involved. Further consider: any potentials for dual use, and especially if there are any biosafety or biosecurity concerns that are not addressed by current administrative controls”. (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#Terry">Terry Johnson, 2013</a>). Interestingly, the security page of 2011 contains details about biosecurity risk assessment. The possible misuse of information is pointed out. At the time of this | + | <p>Nevertheless, iGEM members are supposed to live up to the trust that is put into them by society and “design, build and share biological devices safely” (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#iGEM15">iGEM Safety Page</a>). Aspects of dual use have found focus in Terry Johnson´s call for awareness: iGEM participants, but also participants anywhere in the biotechnological environment, “should be aware of: the organization or organizations overseeing (ones) work, the appropriate Risk Group for the organisms that (one is) working with, and any select agents that might be involved. Further consider: any potentials for dual use, and especially if there are any biosafety or biosecurity concerns that are not addressed by current administrative controls”. (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#Terry">Terry Johnson, 2013</a>). Interestingly, the security page of 2011 contains details about biosecurity risk assessment. The possible misuse of information is pointed out. At the time of this year's project design and conduction neither on the main iGEM page nor on the 2015 page a security page was existent. Nevertheless, the iGEM competition established a safety committee that has members with very deep knowledge about the dual use concern. </p> |
<h3>Conclusions</h3> | <h3>Conclusions</h3> | ||
<p>Facing this dilemma in our own project, we have not found proper guidelines within the competitions to apply to our concerns. While iGEM provides expert council through its safety committee, we find this not to be sufficient to call for awareness of dual use in states of research. As proposed in our description of the ethical debate, this is critical for the planning of research. Therefore, we propose the implementation of biosecurity risk assessment in obligational forms. Since the iGEM competition asks us to be “striving to be conscientious members of the synthetic biology community” (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#iGEM15">iGEM Safety Page</a>), we want to complete this safety and security aspects by finding guidelines for the safe distribution of knowledge and the question of dual use research of concern. As it is an international competition aiming to promote the communication between researchers as well as between them and the public, iGEM could be a role model in considering the dual use dilemma.</p> | <p>Facing this dilemma in our own project, we have not found proper guidelines within the competitions to apply to our concerns. While iGEM provides expert council through its safety committee, we find this not to be sufficient to call for awareness of dual use in states of research. As proposed in our description of the ethical debate, this is critical for the planning of research. Therefore, we propose the implementation of biosecurity risk assessment in obligational forms. Since the iGEM competition asks us to be “striving to be conscientious members of the synthetic biology community” (<a href="https://2015.igem.org/Team:Bielefeld-CeBiTec/Practices/DualUse#iGEM15">iGEM Safety Page</a>), we want to complete this safety and security aspects by finding guidelines for the safe distribution of knowledge and the question of dual use research of concern. As it is an international competition aiming to promote the communication between researchers as well as between them and the public, iGEM could be a role model in considering the dual use dilemma.</p> | ||
Line 172: | Line 172: | ||
<p>Our project is aiming to build a biosensor for detecting ingredients of date rape drugs with the prospect of enabling people to protect themselves. Nevertheless, we focus attention on these ingredients and their availability and hence provide knowledge that might be misused to harm people. We therefore analyzed the legal restriction of the providence of this knowledge not only in our country (Germany), but also in the European Union as confederal institution and in the USA, where iGEM takes place. We did not find laws applying to the publication of this knowledge, which is therefore legally justifiable.</p> | <p>Our project is aiming to build a biosensor for detecting ingredients of date rape drugs with the prospect of enabling people to protect themselves. Nevertheless, we focus attention on these ingredients and their availability and hence provide knowledge that might be misused to harm people. We therefore analyzed the legal restriction of the providence of this knowledge not only in our country (Germany), but also in the European Union as confederal institution and in the USA, where iGEM takes place. We did not find laws applying to the publication of this knowledge, which is therefore legally justifiable.</p> | ||
<h3>Ethics</h3> | <h3>Ethics</h3> | ||
− | <p>While providing this knowledge might lead to misuse, it has benevolent content. By publishing our obtained knowledge, we might inspire others to improve | + | <p>While providing this knowledge might lead to misuse, it has benevolent content. By publishing our obtained knowledge, we might inspire others to improve a sensor for the protection against date rape drugs, but also to build other biosensors detecting harmful substances in beverages in hindsight to our aim to provide a modular, extensible tool for the further creation of biosensors. In addition, our knowledge might raise the awareness of availability of the used chemicals in date rape drugs. This could ultimately lead to a more careful handling of beverages or even the overthought of legal obtainability and restriction of these chemicals, as we caused a broad discussion in the media. These findings lead to our ethical analysis in collaboration with experts from microbiology, law, sociology and ethics. Do the potential benefits of the publication of our results outweigh the potential risk? Since we are not providing knowledge how to synthesize or obtain these drugs, we still focus attention on these substances. Therefore, we decided to apply security risk assessment to our project.</p> |
Line 193: | Line 193: | ||
<p>In our weekly team meeting the upcoming publication of the substance and details about our sensor were discussed in hindsight to potential dual use risk. Experts were contacted, such as the ethics committee at our university, the iGEM safety committee itself and of course our supervisor. Regular oversight by an institution is not yet established.</p> | <p>In our weekly team meeting the upcoming publication of the substance and details about our sensor were discussed in hindsight to potential dual use risk. Experts were contacted, such as the ethics committee at our university, the iGEM safety committee itself and of course our supervisor. Regular oversight by an institution is not yet established.</p> | ||
<li>Minimizing potential risk</li> | <li>Minimizing potential risk</li> | ||
− | <p>We found restriction of publication in this case | + | <p>We found restriction of publication in this case not to be effective to minimize the risk, since we do not provide the knowledge of how to obtain or synthesize the ingredients of the date rape drugs. Said information are obtainable astonishingly easily, therefore our call for awareness and providence of knowledge to create a biosensor contains more benevolent content than potential risk.</p> |
<li>Documentation and communication</li< | <li>Documentation and communication</li< | ||
<p>We documented not only the use of the chemical, but also our concerns about biosecurity issues. We contacted the ethics council of our university that unfortunately is not yet established for biotechnological research. The interview is available in our report. We further contacted the iGEM safety committee for advice on publication. Mrs. Kelly Drinkwater, member of the iGEM safety committee, agreed on our proposed publication.</p> | <p>We documented not only the use of the chemical, but also our concerns about biosecurity issues. We contacted the ethics council of our university that unfortunately is not yet established for biotechnological research. The interview is available in our report. We further contacted the iGEM safety committee for advice on publication. Mrs. Kelly Drinkwater, member of the iGEM safety committee, agreed on our proposed publication.</p> | ||
Line 235: | Line 235: | ||
<p>→ Yes. We focus on the availability of an ingredient of date rape drugs. This potential misused has been evaluated carefully. The benefit of the published knowledge outweighs the potential risk, because we found the critical information already published and easily assessable. Therefore, our knowledge provides protection by creation of a biosensor and raise of the awareness of the potential danger of date rape drugs.</p> | <p>→ Yes. We focus on the availability of an ingredient of date rape drugs. This potential misused has been evaluated carefully. The benefit of the published knowledge outweighs the potential risk, because we found the critical information already published and easily assessable. Therefore, our knowledge provides protection by creation of a biosensor and raise of the awareness of the potential danger of date rape drugs.</p> | ||
<li>In case of collaboration, does the sharing of devices or information create the potential of misuse?</li> | <li>In case of collaboration, does the sharing of devices or information create the potential of misuse?</li> | ||
− | < | + | <p>→ Sharing the device does not contain the risk of misuse. Sharing the information contains the same risk as publication of said knowledge.</p> |
<li>In case of potential risk, did you initiate oversight or seek ethical/legal council or advice?</li> | <li>In case of potential risk, did you initiate oversight or seek ethical/legal council or advice?</li> | ||
<p>→ Yes. We contacted the ethics commission of our university and the iGEM safety committee. Unfortunately, no advice could be given by our ethics commission. The iGEM safety committee agreed with us, that the information we provide is already published and easily accessible and therefore does not contain a risk that would justify the restriction of publication on our wiki. </li> | <p>→ Yes. We contacted the ethics commission of our university and the iGEM safety committee. Unfortunately, no advice could be given by our ethics commission. The iGEM safety committee agreed with us, that the information we provide is already published and easily accessible and therefore does not contain a risk that would justify the restriction of publication on our wiki. </li> |
Revision as of 00:58, 19 September 2015
Dual Use
More than biosafety and biosecurity: Ethics, Laws and Guidelines
Overview
We decided to do an analysis of biosecurity, specifically the dual use issue of our project. While we were scanning the literature for information about our biosensor for detection of date rape drugs, we encountered many sensitive information about the accessibility and (chemical) synthesis of date rape drugs. Those information are publicly availably. Especially the publication of a freely available ingredient raised our concern. In our opinion, this knowledge can create a threat to the health of people, if it is misused.
Because iGEM is an open source competition, we might ourselves provide knowledge that could be of dual use. Since iGEM asks us to be striving to be conscientious members of the synthetic biology community, we informed ourselves about existing biosafety, biosecurity and dual use regulations.
We found the legal situation in Germany, the European Union and the USA to be inconsistent. In addition to these laws, many proposals from various advisory boards and non governmental organizations exist. We provide an overview about the proposals of these organizations and summarize various aspects of the ongoing ethical discussion about the opposing needs freedom of science and regulation of research with possible biosecurity issues. Therefore we contacted several experts from ethics committees, members of the German ethics council, a constitutional lawyer and a law student from the USA, as well as the iGEM safety committee itself. In fruitful discussions we obtained various opinions from different fields of expertise/from different academical point of views/from different perspectives.
In the year 2011, the iGEM main page had a security section, that stated
"As a participant in iGEM, there are three things you can do right now to help us secure our science:
- Fully answer the safety questions that demonstrates that you have thought about how others could misuse your work
- Contribute to community discussions on what needs to go into a code against the use of our science for hostile purposes (see A Community Response)
- Look into what security provisions, such as laws and regulations, are already in place in your country (see Working within the Law)"
(iGEM Security Page 2011)
While the answering of the safety questions is already obligatory, we addressed the laws and regulations as well as the contribution to a community discussion with our analysis and report.
We wondered, why we did not find any biosafety, biosecurity and dual use definitions within the iGEM safety page 2015. A specific security page was not established in the manner of 2011. iGEM offers many regulations and risk assessments concerning biosafety and provides a great infrastructure with its interdisciplinary expert team, the biosafety commission. We want to complete this biosafety and security aspects by finding guidelines for the safe distribution of information and the dual use in research. We propose the implementation of definitions in the safety page and questions aiming for biosecurity and dual use risk assessment in the obligatory safety forms. iGEM has a unique potential in reaching out in education of young researchers to contribute to a responsible research community.
We performed the risk assessment for our project, which, in addition to our public outreach and several expert contacts, influenced our project significantly. It broadened our horizon in the context of interdisciplinary collaboration and communication with the public - to build up to the trust put into us.
We believe, that iGEM can be a role model in raising awareness of biosecurity and dual use risks - for a better international collaboration to create beneficial knowledge.
We briefly summarize our findings on these pages. The detailed report is available as a PDF.